Nuno Pedrosa de Barros

Nuno Pedrosa de Barros

Auto-generated profile, based on publicly available information

Nuno Pedrosa de Barros

Icometrix, 3012 Leuven, Belgium

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in NeuroImage: Clinical
Verified
Journal Article
Open access
HSHanne Struyfs
Hanne Struyfs
DSDiana Maria Sima
Diana Maria Sima
MWMelissa Wittens
Melissa Wittens
ARAnnemie Ribbens
Annemie Ribbens
NBNuno Pedrosa de Barros
Nuno Pedrosa de Barros
DSDirk Smeets
Dirk Smeets
Brain volumes computed from magnetic resonance images have potential for assisting with the diagnosis of individual dementia patients, provided that they have low measurement error and high reliability. In this paper we describe and validate icobrain dm, an automatic tool that segments brain structures that are relevant for differential diagnosis of dementia, such as the hippocampi and cerebral lobes. Experiments were conducted in comparison to the widely used FreeSurfer software. The hippocampus segmentations were compared against manual segmentations, with significantly higher Dice coefficients obtained with icobrain dm (25-75th quantiles: 0.86-0.88) than with FreeSurfer (25-75th quantiles: 0.80-0.83). Other brain structures were also compared against manual delineations, with icobrain dm showing lower volumetric errors overall. Test-retest experiments show that the precision of all measurements is higher for icobrain dm than for FreeSurfer except for the parietal cortex volume. Finally, when comparing volumes obtained from Alzheimer's disease patients against age-matched healthy controls, all measures achieved high diagnostic performance levels when discriminating patients from cognitively healthy controls, with the temporal cortex volume measured by icobrain dm reaching the highest diagnostic performance level (area under the receiver operating characteristic curve = 0.99) in this dataset.

29 February 2016 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
NBNuno Pedrosa de Barros
Nuno Pedrosa de Barros
RMRichard McKinley
Richard McKinley
UKUrspeter Knecht
Urspeter Knecht
RWRoland Wiest
Roland Wiest
JSJohannes Slotboom
Johannes Slotboom

1 July 2017 in Analytical Biochemistry
Verified
Journal Article
Closed access
NBNuno Pedrosa de Barros
Nuno Pedrosa de Barros
JSJohannes Slotboom
Johannes Slotboom

10 October 2017 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
SKSreenath P. Kyathanahally
Sreenath P. Kyathanahally
VMVictor Mocioiu
Victor Mocioiu
NBNuno Pedrosa de Barros
Nuno Pedrosa de Barros
JSJohannes Slotboom
Johannes Slotboom
AWAlan J. Wright
Alan J. Wright
RKRoland Kreis
Roland Kreis

7 February 2017 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
NBNuno Pedrosa de Barros
Nuno Pedrosa de Barros
RMRichard McKinley
Richard McKinley
RWRoland Wiest
Roland Wiest
JSJohannes Slotboom
Johannes Slotboom

1 October 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
EGEmily M. Ullrich Gavilanes
Emily M. Ullrich Gavilanes
LBLaura M. Bartos
Laura M. Bartos
JGJonathan A. Gernert
Jonathan A. Gernert
CCCarla Ares Carral
Carla Ares Carral
DNDiego Ruiz Navarro
Diego Ruiz Navarro
MKMartin Kerschensteiner
Martin Kerschensteiner
Gray matter pathology, including the formation of cortical lesions, predicts progression in people with multiple sclerosis (PwMS). Here, we investigated whether positron emission tomography (PET) imaging using the synaptic vesicle protein 2A (SV2A)–targeting radioligand [ 18 F]UCB-H could help to detect and monitor synapse loss, an early feature of gray matter pathology in MS. First, we confirmed that SV2A is a suitable marker of synapse density in MS by analyzing SV2A mRNA and protein expression in cortical gray matter. We then used a mouse model of cortical MS pathology to demonstrate that SV2A-PET imaging can detect synapse loss in cortical lesions and that synapse densities measured by PET imaging correspond to the densities of genetically and immunohistochemically labeled synapses in the same lesions. Last, we performed SV2A-PET imaging in a total of 31 PwMS at different stages of the disease process, showing that PET imaging can detect synapse loss in cortical MS lesions in vivo. Moreover, we found that interhemispheric asymmetries in SV2A-PET tracer uptake can be leveraged to uncover further cortical alterations, the volume of which was more than 20-fold larger than the cortical lesion area detected by MRI. The extent of these PET-defined areas of cortical synapse pathology was larger in the progressive stage of the disease and correlated with the disability and cognitive performance of the same individuals. SV2A-PET imaging thus unmasked clinically relevant cortical pathology in MS thereby providing a promising tool to detect and monitor disease progression.